NOV - Novo Nordisk A/S - Stock Price & Dividends

Exchange: XETRA Stock Exchange • Country: Denmark • Currency: EUR • Type: Common Stock • ISIN: DK0062498333

Insulin, Diabetes, Obesity, Hormone, Growth Hormone

Novo Nordisk A/S is a global pharmaceutical company that discovers, develops, and distributes innovative medicines to improve the lives of people worldwide.

Headquartered in Bagsvaerd, Denmark, the company operates in two main segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment focuses on developing treatments for diabetes, obesity, cardiovascular diseases, and emerging therapy areas, while the Rare Disease segment concentrates on rare blood disorders, rare endocrine disorders, and hormone replacement therapy.

Novo Nordisk A/S is a leading manufacturer of insulin pens, growth hormone pens, and injection needles, making it easier for patients to manage their conditions. The company is also at the forefront of digital health innovation, offering smart solutions such as smart insulin pens and Dose Check, an insulin dose guidance application that helps patients track and manage their insulin doses more effectively.

In addition to its internal research and development efforts, Novo Nordisk A/S collaborates with other companies, such as Aspen Pharmaceuticals, to produce insulin products and expand its reach. With a rich history dating back to 1923, the company has established itself as a trusted partner in the global healthcare industry.

Today, Novo Nordisk A/S is a global leader in diabetes care, with a strong presence in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. The company's commitment to innovation, quality, and patient care has earned it a reputation as a reliable and trusted partner in the pharmaceutical industry.

For more information, please visit the company's website at https://www.novonordisk.com.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for NOV - Novo Nordisk A/S  - Stock Price & Dividends

NOV Stock Overview

Market Cap in USD 650,707m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception

NOV Stock Ratings

Growth 5y 97.6
Fundamental 63.3
Dividend 72.63
Rel. Performance vs Sector 1.47
Analysts -
Fair Price Momentum 187.12 EUR
Fair Price DCF 392.48 EUR

NOV Dividends

Dividend Yield 12m 1.02%
Yield on Cost 5y 11.22%
Dividends CAGR 5y 11.67%
Payout Consistency 95.0%

NOV Growth Ratios

Growth 12m 79.83%
Growth Correlation 12m 85%
Growth Correlation 3m 56%
CAGR 5y 58.73%
CAGR/Mean DD 5y 15.05
Sharpe Ratio 12m 2.18
Alpha vs SP500 12m 61.76
Beta vs SP500 5y weekly 0.68
ValueRay RSI 0.44
Volatility GJR Garch 1y 47.01%
Price / SMA 50 -8.84%
Price / SMA 200 9.46%
Current Volume 112.7k
Average Volume 20d 61.2k

External Links for NOV Stock

Tweets
XStocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of NOV stocks?
As of July 19, 2024, the stock is trading at EUR 117.00 with a total of 112,739 shares traded.
Over the past week, the price has changed by -8.74%, over one month by -10.76%, over three months by +1.11% and over the past year by +79.00%.
What are the forecast for NOV stock price target?
According to ValueRays Forecast Model, NOV Novo Nordisk A/S will be worth about 206.8 in July 2025. The stock is currently trading at 117.00. This means that the stock has a potential upside of +76.74%.
Issuer Forecast Upside
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 206.8 76.7

The Story of Novo Nordisk A/S

History

Novo Nordisk A/S, with its rich history that begins in early 20th century Denmark, stands today as a beacon in the healthcare industry, particularly in diabetes care. Founded from the merger of two small Danish companies, it has grown over the decades into a global leader in this vital field of medicine. Its journey from producing the first insulin in Scandinavia to innovating diabetes care solutions reflects its deep-rooted commitment to improving patient outcomes.

Core Business

At its core, Novo Nordisk is dedicated to defeating diabetes. Its portfolio heavily emphasizes insulin and other diabetes treatments, including modern insulins and oral antidiabetic drugs. This focus is driven by a mission to discover and develop innovative medicines to help people with diabetes lead longer, healthier lives. Beyond insulin, Novo Nordisk has also ventured into treatments for obesity, another critical healthcare area, further showing its commitment to confronting global health challenges.

Side Businesses

While Novo Nordisk’s primary focus remains on diabetes care, the company also operates in other areas of the healthcare sector. These include hemophilia care, growth hormone therapy, and hormone replacement therapies, extending its expertise beyond a singular focus and into a broader healthcare context. These varied interests underpin Novo Nordisk's ambition to provide a wide range of treatments for complex medical conditions.

Current Market Status

Today, Novo Nordisk continues to stand tall in the healthcare market, with a robust global presence that spans dozens of countries. Despite the challenges in the pharmaceutical industry, including competitive markets and regulatory pressures, the company has maintained a strong financial performance. Its commitment to innovation in diabetes care and beyond has ensured its position as a leader in the sector, making it a key player in today's global healthcare landscape.